A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
This study has been completed.
First Posted: January 11, 2007
Last Update Posted: July 2, 2012
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||January 2011|
|Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||June 27, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240.